Home / Stocks / Bharat Parenterals Ltd.
BPLPHARMA

Bharat Parenterals Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,401.0

Change

-39.0 (-1.6%)

Open

₹2,391.1

Prev. Close

₹2,440.0

Day High

₹2,468.3

Day Low

₹2,375.0

Volume Analysis

Traded

15,765

Delivered

5,445

Delivery %

34.54%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Trading within 3% of its 52-week high (₹2295.0)

Weaknesses (3)

  • •Low return on equity (-2.54%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (49/100)

Opportunities (1)

  • •Strong 3-year revenue growth (16.5%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,547.84 ₹2,508.07 ₹2,454.54 ₹2,414.77 ₹2,361.24 ₹2,321.47 ₹2,267.94
Fibonacci ₹2,508.07 ₹2,472.43 ₹2,450.41 ₹2,414.77 ₹2,379.13 ₹2,357.11 ₹2,321.47
Camarilla ₹2,426.66 ₹2,418.11 ₹2,409.55 ₹2,414.77 ₹2,392.45 ₹2,383.9 ₹2,375.34

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

+25.72%

1 Month

+36.51%

3 Months

+71.86%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹375.19

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

-6.05%

Net margin -2.53% × asset turnover 1.03x × equity multiplier 2.32x

Company Overview

Sector

Healthcare

Market Cap

₹1,522 Cr

P/E (TTM)

1227.0

ROE

-2.54%

Book Value

₹482.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Bharat Parenterals Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Momentum (94/100), while Cash Flow (16/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹2295.0); low return on equity (-2.54%); promoter holding is falling. Strong 3-year revenue growth (16.5%).

TopFund Score — Fundamentals Quality

49/100 — Weak

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

89

Growth

69

Valuation

21

Cash Flow

16

Corporate Governance

43

Momentum

94

Institutional Ownership

41

Business Quality

24

Risk & Volatility

62

Liquidity

23

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 4.59 times its book value
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of -0.79% over last 3 years.
  • −Company has high debtors of 159 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Innoxel received USFDA EIR on Nov 4, 2026; Vadodara facility cleared for commercial injectable operations.

Q2FY27 earnings conference call audio recording hosted on company website on October 30, 2026.

Please find the enclosed copies of the newspaper publication regarding unaudited standalone and Consolidate Financial result for the quarter and half-year ended on September 30, …

Investor Presentation for the Quarter and Half Year ended on September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 60 60 68 93 72 72 104 116 65 65 100 94 136
Expenses + 55 53 67 88 79 69 102 102 64 63 100 85 113
Operating Profit 4 7 1 4 -8 4 2 14 1 2 -1 9 24
OPM % 7.0% 11.0% 1.5% 4.8% -11.0% 5.0% 2.1% 12.0% 1.3% 2.7% -0.5% 9.0% 17.0%
Other Income + 3 1 3 3 4 3 2 1 4 1 4 1 3
Interest 1 1 1 3 3 3 4 4 3 3 3 2 3
Depreciation 2 2 4 9 9 9 9 9 9 8 9 9 9
Profit before tax 5 5 -1 -5 -15 -6 -8 3 -7 -8 -8 -2 14
Tax % 46.0% 33.0% 88.0% 85.0% 14.0% 43.0% 14.0% 134.0% 18.0% 17.0% -3.0% 138.0% 16.0%
Net Profit + 2 4 -3 -9 -18 -8 -9 -1 -9 -10 -8 -4 12
EPS in Rs 6 7 -1 2 -12 -2 -7 12 -11 -6 -7 1 14
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -27 1 33 32 20 21 53 25 -10 -10 -4 -19 111

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 119 124 111 137 220 228 205 212 218 261 340 345 395
Expenses + 108 114 105 124 191 200 179 183 198 234 337 330 362
Operating Profit 11 10 7 12 29 28 25 29 20 27 4 16 33
OPM % 9.0% 8.0% 6.0% 9.0% 13.0% 12.0% 12.0% 14.0% 9.0% 10.0% 1.1% 4.6% 8.0%
Other Income + 4 5 8 7 13 11 9 7 12 5 11 10 9
Interest 2 1 1 1 1 1 1 1 3 4 13 13 11
Depreciation 4 4 6 6 6 6 6 7 6 9 35 34 35
Profit before tax 9 9 7 13 35 33 27 28 24 19 -34 -21 -4
Tax % 15.0% 31.0% 8.0% 29.0% 39.0% 26.0% 25.0% 25.0% 33.0% 44.0% 29.0% 27.0% —
Net Profit + 7 6 7 9 21 24 20 21 16 11 -44 -27 -10
EPS in Rs 13 11 12 16 37 42 36 36 28 25 -18 -12 2
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 3.0% 4.0% -5.0% -8.0% —
Sales growth 4 — -10 23 61 4 -10 4 3 20 30 1 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 44 51 58 67 88 112 138 160 177 191 324 315 325
Borrowings + 16 19 6 9 5 1 12 18 50 158 180 146 160
Other Liabilities + 50 44 40 50 60 68 43 42 118 149 138 145 171
Total Liabilities 116 120 110 132 159 188 199 226 350 504 649 613 664
Fixed Assets + 29 35 31 34 35 33 45 41 42 211 252 255 245
CWIP 0 0 0 0 1 12 0 26 99 25 31 35 36
Investments 0 0 1 1 1 0 43 11 0 0 5 6 62
Other Assets + 87 85 79 98 121 142 111 148 209 268 360 317 320
Total Assets 116 120 110 132 159 188 199 226 350 504 649 613 664
Equity Capital 6 6 6 6 6 6 6 6 6 6 7 7 7

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 0 0 -2 6 20 14 24 -1 22 -5 -27 38
Cash from Investing Activity + 0 0 -2 -8 -9 -13 -43 -7 -78 -105 -137 9
Cash from Financing Activity + 0 0 -8 4 -4 -3 10 9 61 110 156 -47
Net Cash Flow 0 0 -11 2 7 -1 -8 2 4 1 -8 1
Free Cash Flow 0 0 -4 -2 12 0 24 -40 -68 -108 -56 -1
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 0 0 -8 73 107 87 123 16 150 18 -444 305

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 73.84% → 67.2%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 26.15% 26.72% 26.72% 33.98% 32.16% 32.15% 32.16% 32.16% 32.17% 31.65% 31.31% 31.4%
Promoters 73.84% 73.27% 73.27% 65.35% 67.2% 67.2% 67.19% 67.19% 67.19% 67.17% 67.2% 67.2%
FII 0.0% 0.0% 0.0% 0.08% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
DII 0.01% 0.01% 0.01% 0.57% 0.54% 0.54% 0.54% 0.54% 0.54% 1.07% 1.38% 1.29%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Bharat Parenterals Ltd. (this stock) 1,522 1227.0 4.59 -2.54%
Amrutajan Health Ltd 1,461 71.7 13.58 20.0%
Jagsonpal Pharmaceuticals 1,402 — 5.82 —
Fischer Medical Venture L 1,642 144.0 3.52 8.91%
Krsnaa Diagnostics Ltd 1,661 16.9 1.6 10.9%
Fermenta Biotech Ltd. 1,367 29.4 3.27 17.3%
Tarsons Products Limited 1,678 205.0 2.65 2.44%

Which Mutual Funds Hold Bharat Parenterals Ltd.?

Frequently Asked Questions about Bharat Parenterals Ltd.

Community Sentiment

What are other investors saying about Bharat Parenterals Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.